Mirae Asset Global Investments Co. Ltd. Cuts Position in Repligen Corporation $RGEN

Mirae Asset Global Investments Co. Ltd. lessened its position in shares of Repligen Corporation (NASDAQ:RGEN) by 21.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,051 shares of the biotechnology company’s stock after selling 4,211 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Repligen were worth $2,466,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC grew its holdings in Repligen by 1.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock valued at $584,000 after buying an additional 75 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Repligen by 17.0% in the 3rd quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 97 shares during the period. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Repligen by 0.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after purchasing an additional 100 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its holdings in shares of Repligen by 1.0% in the 3rd quarter. Northwestern Mutual Investment Management Company LLC now owns 11,787 shares of the biotechnology company’s stock worth $1,576,000 after purchasing an additional 121 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

RGEN opened at $124.40 on Thursday. The business has a fifty day moving average of $123.91 and a 200 day moving average of $146.04. Repligen Corporation has a 52-week low of $109.66 and a 52-week high of $175.77. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.02 billion, a P/E ratio of 146.35, a PEG ratio of 2.59 and a beta of 1.19.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The company had revenue of $197.91 million during the quarter, compared to analysts’ expectations of $192.23 million. During the same quarter in the previous year, the business earned $0.44 EPS. Repligen’s revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, sell-side analysts anticipate that Repligen Corporation will post 1.97 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Wells Fargo & Company dropped their target price on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Canaccord Genuity Group dropped their target price on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday. Finally, Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $170.93.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.